

December 3, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub : Disclosure of Related Party Transactions for the half year ended 30th September 2019.
Ref : Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended 30th September 2019.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Reddy

B Adi Reddy
Company Secretary



Encl: as above.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

i) Names of related parties and description of relationship

a) Joint ventures

Novagen Pharma (Pty) Limited, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)
 Eugia Pharma Specialities Limited, India (Joint Venture of a step-down subsidiary, Curepro parenterals Ltd)
 Tergene Biotech Private Limited, India
 Raidurgam Developers Limited, India (formerly known as Aurobindo Antibiotics limited, India)
 Purple Bellflower (Pty)Ltd, South Africa (Joint Venture of a step-down subsidiary, Aurogen South Africa (Pty) Ltd, South Africa)
 Luoxin Aurovitas Pharm (Chengdu) Co. Ltd. (Joint Venture of a step-down subsidiary, Helix Healthcare B.V.)

b) Enterprises over which key management personnel or their relatives exercise significant influence

Pravesh Industries Private Limited, India
 Sri Sai Packaging, India (Partnership firm)
 Trident Chemphar Limited, India
 Axis Clinicals Limited, India
 Pranit Packaging Private Limited, India
 SGD Pharma India Limited (formerly Cogent Glass Limited), India
 Orem Access Bio Inc, India
 Veritaz Healthcare Limited, India
 Axis Clinicals LLC, USA
 Crest Cellulose Private Limited, India
 East Pharma Technologies, India (Partnership firm)
 Axis Clinicals Latina SA DE CV, Mexico
 Gelcaps Industries, India
 Aurobindo Foundation, India
 Giyaan Pharma Private Limited, India
 Alcedo Pharmachem Private Limited, India
 Ambipack Industries, India

c) Key managerial personnel

Mr. K. Nityananda Reddy, Whole-time Director
 Dr. M. Sivakumaran, Whole-time Director
 Mr. M. Madan Mohan Reddy, Whole-time Director
 Mr. P. Sarath Chandra Reddy, Whole-time Director
 Mr. N. Govindarajan, Managing Director
 Mr. Santhanam Subramanian, Chief Financial Officer
 Mr. B. Adi Reddy, Company Secretary
 Mr. K. Ragunathan, Non-executive Chairman and Independent Director
 Mr. M. Sitarama Murty, Independent Director
 Dr. (Mrs.) Avnit Bimal Singh, Independent Director
 Mr. P. Venkata Ramprasad Reddy, Non Executive promoter director
 Mrs. Savitha Mahajan, Independent Director

d) Relatives to key managerial personnel

Mr. Vishnu M Sriram (Son in law of Dr. M. Sivakumaran, Wholetime Director)

ii) Transactions with related parties

a. Transactions with joint ventures

	Half Year ended 30 September 2019
Raidurgam Developers Limited	
Investment in optionally convertible debentures	64.0
Interest accrued	12.2
Novagen Pharma (Pty) Limited, South Africa	
Sale of products	92.3
Sale of services	17.7
Dividend received	24.0
Eugia Pharma Specialities Ltd, India	
Sale of products	60.0
Purchases	1,368.1
Tergene Biotech Pvt. Ltd, India	
Investment in 10.5% Cumulative Redeemable Preference shares	14.0



b. Transactions with enterprises over which key management personnel or their relatives exercise significant influence

	Half Year ended 30 September 2019
Pravsha Industries Private Limited, India	
Purchases	1,684.7
Sri Sai Packaging, India	
Sale of products	0.2
Purchases	120.3
Axis Clinicals Limited, India	
Purchase of services	883.6
Purchase of Fixed assets	70.9
Axis Clinicals LLC, USA	
Purchase of services	55.4
Purchase of Fixed Assets	20.7
Axis Clinicals Latina SA DE CV, Mexico	
Purchase of services	0.8
Trident Chemphar Limited, India	
Purchases	616.8
Purchase of services	62.9
Pranit Packaging Private Limited, India	
Purchases	123.5
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Purchases	633.4
Purchase of services	0.3
Orem Access Bio Inc, India	
Purchases	170.0
Veritaz Healthcare Limited, India	
Sale of products	113.5
Rent received	0.2
Crest Cellulose Private limited, India	
Purchases	253.5
East Pharma Technologies, India	
Purchases	46.7
Gelcaps Industries, India	
Purchases	212.6
Aurobindo Foundation, India	
Contribution towards CSR activities	200.0
Giyaan Pharma Private Limited, India	
Sale of products	5.2
Alcedo Pharmachem Private Limited, India	
Purchases	95.0
Ambipack Industries, India	
Purchases	54.3

c. Transactions with key managerial personnel or their relatives

	Half Year ended 30 September 2019
Mr. K Nityananda Reddy	
Managerial remuneration	6.8
Rent expense	1.4
Dr. M Sivakumaran	
Managerial remuneration	6.8
Mr. M Madan Mohan Reddy	
Managerial remuneration	18.4
Mr. P Sarath Chandra Reddy	
Managerial remuneration	3.9
Mr. Vishnu M Sriram	
Remuneration	3.0
Mr.N Govindarajan	
Managerial Remuneration	31.4
Mr.Santhanam Subramanian	
Remuneration	9.6
Mr.B. Adi Reddy	
Remuneration	2.1
Mr. P.Venkata Ramaprasad Reddy	
Director sitting fees	0.2
Mr. K.Ragunathan, Non-executive Chairman and Independent Director	
Director sitting fees	0.5
Mr. M. Sitarama Murty, Independent Director	
Director sitting fees	0.3
Mrs.Avni Bimal Singh, Independent Director	
Director sitting fees	0.4
Mrs.Savitha Mahajan, Independent Director	
Director sitting fees	0.3

Note:

Managerial remuneration does not include provision for gratuity and leave encashment, which is determined for the Company as a whole.



Aurobindo Pharma Limited
 Disclosure of related party transactions on a consolidated basis for the half year ended 30 September 2019
 (All amounts are in Indian Rupees in millions)

iii) Closing balances of related parties	
a. Balances with Joint ventures at the year end	
	As at 30 September 2019
Novagen Pharma (Pty) Limited, South Africa	
Balance receivable	71.4
Eugia Pharma Specialities Limited, India	
Balance receivable	45.9
Balance payable	944.9
b. Balances with enterprises over which key management personnel or their relatives exercise significant influence at the year end.	
	As at 30 September 2019
Pravesha Industries Private Limited, India	
Balance payable	982.0
Sri Sai Packaging, India	
Balance payable	25.5
Axis Clinicals Limited, India	
Balance payable	216.6
Axis Clinicals LLC, USA	
Balance receivable	2.6
Trident Chemphar Limited, India	
Balance payable	74.3
Pranit Packaging Private Limited, India	
Balance receivable	0.8
Balance payable	27.2
SGD Pharma India Limited (formerly Cogent Glass Limited), India	
Balance payable	355.5
Veritaz Healthcare Limited, India	
Balance receivable	87.4
Orem Access Bio Inc, India	
Balance payable	80.1
Crest Cellulose Private Limited, India	
Balance payable	68.2
East Pharma Technologies, India	
Balance payable	15.2
Gelcaps Industries, India	
Balance receivable	1.7
Balance payable	89.0
Giyaan Pharma Private Limited, India	
Balance receivable	3.3
Alcedo Pharmachem Private Limited, India	
Balance payable	65.3
Ambipack Industries, India	
Balance payable	17.5
c. Balances with with key managerial personnel at the year end	
	As at 30 September 2019
Mr. K Nityananda Reddy	
Balance payable	0.2

